Novo Nordisk and AWS team up to supercharge drug discovery with AI
The race to bring new therapies to patients just got a major boost. Novo Nordisk and Amazon Web Services (AWS) have launched a strategic partnership that embeds agentic AI directly into early-stage drug research, with the goal of shrinking the long and costly journey from identifying a biological target to dosing the first human.
At the heart of the collaboration is a new co-innovation hub in London, where Novo Nordisk scientists and AWS engineers, AI specialists, and applied scientists will work side-by-side. The setup is designed to eliminate handoffs between computational analysis and laboratory work, streamlining how potential drug candidates move through early development. AWS becomes Novo Nordisk’s preferred cloud provider, integrating its cloud infrastructure, AI services, and life sciences technologies into the company’s existing research workflows.
From chatbots to biology models
Novo Nordisk already relies on AWS for internal AI workloads. Over 25,000 employees use a generative AI platform built on Amazon Bedrock, powering more than 2,500 chatbot use cases for tasks like information retrieval and document drafting in non-regulated processes. One deployment processes over 26,000 prompts monthly across roughly 140,000 documents. In clinical-study documentation, a system using Anthropic’s Claude 3.5 through Amazon Bedrock cut generation time by more than 90%, reducing work that once involved 40 to 50 people and up to 15 weeks to minutes for a team of three—while still involving medical review and validation.
AI agents enter the lab
The new phase extends AI into core research. AWS’s Amazon Bio Discovery brings more than 40 biological AI models to researchers, enabling AI agents to select and coordinate models for tasks such as identifying potential drug targets, designing therapies, and analyzing biological data. The platform can generate and rank drug candidates before they are synthesized and tested in the lab. Experimental results then feed back into the computational workflow, allowing models to refine themselves in a continuous loop.
Why it matters
This isn’t just another cloud deal: it’s an attempt to shorten the earliest, riskiest phase of drug discovery by merging AI-driven insight with deep therapeutic expertise. For patients waiting for treatments, faster target-to-dose timelines could mean earlier access to new therapies. For the industry, it signals a shift toward tighter integration of AI agents in R&D, not just as tools, but as active collaborators in the scientific process. The London hub also sets a model for how pharma and cloud providers can co-develop solutions on the ground, reducing friction between data science and the bench.
Source: AI News. AI-assisted editorial synthesis — TechnoExpress.